Hillhouse-Backed Biotech Firm I-Mab Eyes $100M In US IPO

I-Mab Biopharma, a Chinese-clinical stage biopharmaceutical company, has filed for an up to US$100 million IPO of American Depository Shares (ADS) on the Nasdaq on Tuesday.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in